Financial Information
This section of the Zynex Medical InvestorRoom houses up to date financial reporting information and interactive tools to provide you with the resources you need to manipulate and understand our current financial standing.
Please note: All data in this section is provided by a 3rd party provider and may be delayed up to 20 minutes. Zynex Medical assumes no responsibility for the accuracy of this data and provides it for informational purposes only.
NASDAQZYXI
| Beta | 0.48 |
|---|---|
| Shares Outstanding | 32.2M |
| Average Volume (10 days) | 119.2K |
| Qtrly Dividend (Ann. Yield) | -- (--) |
Analyst Views
| Current Mean Recommendation | Strong Buy |
|---|
| Strong Buy | 2 | |
|---|---|---|
| Buy | 1 | |
| Hold | 0 | |
| Underperform | 0 | |
| Sell | 0 |
Recent Insider Transactions
Daniel J. Moorhead CHIEF FINANCIAL OFFICER | (6,084) Dispose Mar 25, 2024 |
|---|---|
Lucsok Anna CHIEF OPERATING OFFICER | (7,672) Dispose Mar 25, 2024 |
Thomas Sandgaard PRESIDENT, CEO AND CHAIRMAN | (2,268) Dispose Mar 25, 2024 |
Daniel J. Moorhead CHIEF FINANCIAL OFFICER | 5,000 Acquire Mar 5, 2024 |
Lucsok Anna Chief Operating Officer | 5,000 Acquire Jan 27, 2024 |
